Analía Mykietiuk
A5077283572- Pneumonia and Respiratory Infections
- Respiratory viral infections research
- COVID-19 Clinical Research Studies
- Nosocomial Infections in ICU
- Influenza Virus Research Studies
- Respiratory and Cough-Related Research
- Streptococcal Infections and Treatments
- SARS-CoV-2 and COVID-19 Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Antibiotic Resistance in Bacteria
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Urinary Tract Infections Management
- Antibiotic Use and Resistance
- Neutropenia and Cancer Infections
- COVID-19 and healthcare impacts
- Herpesvirus Infections and Treatments
- Pediatric Urology and Nephrology Studies
- Long-Term Effects of COVID-19
- Sepsis Diagnosis and Treatment
- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Amoebic Infections and Treatments
- Immune Cell Function and Interaction
- Antibiotics Pharmacokinetics and Efficacy
- Parasitic Infections and Diagnostics
Instituto Médico Platense
2016-2025
Instituto de Efectividad Clínica y Sanitaria
2013-2020
Cempra Pharmaceuticals (United States)
2015
Hospital Italiano La Plata
2013-2014
Helios Salud
2013
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
2001-2009
Bellvitge University Hospital
2001-2006
Institut d'Investigació Biomédica de Bellvitge
2006
Universitat de Barcelona
2006
<h3>Background</h3> Health care–associated pneumonia (HCAP) has been proposed as a new category of respiratory infection. However, limited data exist to validate this entity. We aimed ascertain the epidemiology, causative organisms, antibiotic susceptibilities, and outcomes empirical therapy for HCAP requiring hospitalization. <h3>Methods</h3> Observational analysis prospective cohort nonseverely immunosuppressed hospitalized adults with pneumonia. Patients who had recent contact health care...
Importance Immune dysregulation contributes to poorer outcomes in COVID-19. Objective To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added standard care for COVID-19 pneumonia. Design, Setting, and Participants Randomized, double-masked, placebo-controlled clinical trial using a master protocol immunomodulators treatment of participants hospitalized with The results 3 substudies are reported from 95 hospitals at 85 research sites the US Latin America....
Ceftaroline (active form of the prodrug ceftaroline fosamil) is a novel cephalosporin with activity against pathogens commonly associated community-acquired pneumonia (CAP), including Streptococcus pneumoniae and Gram-negative pathogens. This randomized, double-blind, Phase III study evaluated efficacy safety fosamil in treating patients CAP. The primary objective was to determine non-inferiority [lower limit 95% confidence interval (CI) ≥ -10%] clinical cure rates achieved compared those...
Cryptogenic liver abscesses (CLA) caused by hypervirulent Klebsiella pneumoniae (hvKP) strains are emerging in Western countries. The aim of the study was to describe clinical characteristics patients from Argentina with hvKP-related CLA as well molecular analysis isolated strains. A retrospective chart review 15 hospitalized 8 hospitals between October 2015 and November 2018 performed. PCR assays for genes associated capsular multilocus sequence typing (MLST) determination virulence factors...
Background Clinical features and outcomes of SARS-CoV-2 infections diverge in different countries. The aim this study was to describe clinical characteristics a cohort patients hospitalized with Argentina. Methods Multicenter prospective ≥18 years-old confirmed infection consecutively admitted 19 hospitals Multivariable logistic regression models were used identify variables associated 30-day mortality admission intensive care unit (ICU). Results A total 809 analyzed. Median age 53 years,...
Immunocompromised patients infected with influenza exhibit prolonged viral shedding and higher risk of resistance. Optimized treatment strategies are needed to reduce the antiviral This phase IIIb, randomized, double-blind study (NCT00545532) evaluated conventional-dose or double-dose oseltamivir for in immunocompromised patients. Patients primary secondary immunodeficiency infection were randomized 1:1 receive (75 mg adolescents/adults [≥ 13 years]; 30–75 by body weight children [1–12...
We retrospectively assessed the renal toxicity associated with use of intravenous colistin. Fifty-four patients multidrug-resistant Acinetobacter infections were included. At end therapy 6/54 (11%) suffered impairment. Renal impairment colistin is less frequent than initially reported.
BackgroundStatins have immunomodulatory properties and hinder Candida growth. However, it is unknown whether they may improve prognosis in patients with candidemia. We sought to determine the effect of prior statin use on clinical outcomes suffering Methods FindingsMulticenter cohort study hospitalized adults candidemia between 2005 2011 six hospitals Spain, Brazil Argentina. Of 326 candidemias, 44 (13.5%) occurred users 282 (86.5%) non-users. The median value APACHE II at diagnosis was...
Abstract Background Outcome data from prospective follow-up studies comparing infections with different influenza virus types/subtypes are limited. Methods Demographic, clinical characteristics and outcomes for adults laboratory-confirmed A(H1N1)pdm09, A(H3N2), or B were compared in 2 cohorts enrolled globally 2009 through 2015. Logistic regression was used to compare among type/subtypes. Results Of 3952 outpatients, 1290 (32.6%) had A(H1N1)pdm09 infection, 1857 (47.0%) 805 (20.4%) B. 1398...
Immune dysregulation contributes to poorer outcomes in severe Covid-19. Immunomodulators targeting various pathways have improved outcomes. We investigated whether infliximab provides benefit over standard of care.We conducted a master protocol investigating immunomodulators for potential treatment participants hospitalized with Covid-19 pneumonia. report results (single dose infusion) versus shared placebo both care. Primary outcome was time recovery by day 29 (28 days after randomization)....
BACKGROUNDAntibody-based therapies for respiratory viruses are of increasing importance. The INSIGHT 006 trial administered anti-influenza hyperimmune intravenous immunoglobulin (Flu-IVIG) to patients hospitalized with influenza. Flu-IVIG treatment improved outcomes in influenza B but showed no benefit A.METHODSTo probe potential mechanisms utility, sera collected from A or (IAV IBV) were analyzed antibody isotype/subclass and Fcγ receptor (FcγR) binding by ELISA, bead-based multiplex, NK...
We investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19.We conducted master protocol investigate immunomodulators potential treating Covid-19 and report results abatacept. Intravenous abatacept (one-time dose 10 mg/kg, maximum 1000 mg) plus standard of care (SOC) was compared shared placebo SOC. Primary outcome time-to-recovery by day 28. Key secondary endpoints included 28-day...
Ritonavir strongly inhibits cytochrome P450, thus altering the metabolism of other drugs. We report on an HIV-positive man who, his 13th day ritonavir therapy, developed severe ergotism after self-administration low doses ergotamine. Drug interactions, degree responsibility patient and availability over-the-counter medications must be considered when prescribing antiretroviral therapy.